Stock RAC RACE ONCOLOGY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Race Oncology Limited

Equities

RAC

AU000000RAC3

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 07:10:13 28/06/2024 BST 		5-day change 1st Jan Change
1.825 AUD +1.11% Intraday chart for Race Oncology Limited -0.82% +117.26%
06-26 Race Oncology Concludes GLP Non-clinical Toxicology and Safety Pharmacology Studies for RC220 Bisantrene; Shares Jump 10% MT
06-20 Race Oncology Appoints George Clinical for RC220 Bisantrene Phase 1 Trial MT

Valuation

Fiscal Period: June 2023 2024 2025 2026
Capitalization 1 199.8 310.8 - -
Enterprise Value (EV) 1 199.8 301.5 277.3 289.3
P/E ratio -19.9 x -25.3 x -23.1 x -19.8 x
Yield - - - -
Capitalization / Revenue - 77.7 x 72.3 x 60.9 x
EV / Revenue - 75.4 x 64.5 x 56.7 x
EV / EBITDA - -26 x -20.8 x -18.8 x
EV / FCF - -26.4 x -21 x -18.8 x
FCF Yield - -3.78% -4.76% -5.32%
Price to Book - 18.3 x - 18.3 x
Nbr of stocks (in thousands) 163,069 170,290 - -
Reference price 2 1.225 1.825 1.825 1.825
Announcement Date 30/08/23 - - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2023 2024 2025 2026
Net sales 1 - 4 4.3 5.1
EBITDA 1 - -11.6 -13.3 -15.4
EBIT 1 - -11.9 -13.6 -15.7
Operating Margin - -297.5% -316.28% -307.84%
Earnings before Tax (EBT) 1 - -11.7 -13.5 -15.7
Net income 1 -9.923 -11.7 -13.5 -15.7
Net margin - -292.5% -313.95% -307.84%
EPS 2 -0.0617 -0.0720 -0.0790 -0.0920
Free Cash Flow 1 - -11.4 -13.2 -15.4
FCF margin - -285% -306.98% -301.96%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 30/08/23 - - -
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2023 2024 2025 2026
Net Debt 1 - - - -
Net Cash position 1 - 9.3 33.5 21.5
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 - -11.4 -13.2 -15.4
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share 2 - 0.1000 - 0.1000
Cash Flow per Share 2 - -0.0700 -0.0800 -0.0800
Capex 1 - - - -
Capex / Sales - - - -
Announcement Date 30/08/23 - - -
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
RACE ONCOLOGY LIMITED Stock Race Oncology Limited
+117.26% 207M
LONZA GROUP AG Stock Lonza Group AG
+38.65% 39.36B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 30.74B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.92B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.61% 10.64B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RAC Stock
  4. Financials Race Oncology Limited